


COVID-19 – [SARS-CoV-2](#)

Antibodies

- [SARS-CoV-2](#)
- [COVID-19](#)
- [SARS-CoV-2](#)
- [SARS-CoV-2](#)

References

Synowiec et al., 2021 [SARS-CoV-2](#) [1A](#) [1B](#)




**1A** SARS-CoV-2 COVID-19 **A**: cat. no. [HS-452 011](#), 1:1000; **B**: cat. no. [HS-452 111](#), 1:500 **COVID-19** **Ventana Benchmark XT**: 100µm

Dres. Krasemann/Heinrich/Pfefferle/UKE/

SARS-CoV-2 RNA: Synowiec et al., 2021 **2**

SARS - Virus



**SYSY | HistoSure**

2 SARS-CoV-2 RNA Pizzato et al., 2022 RNA


Magazine et al., 2022 WHO SARS-CoV-2 VOCs  $\alpha$   $\beta$   $\gamma$   $\delta$  omicron Magazine et al., 2022 RNA  $\alpha$  omicron R203K+G204R SARS-CoV-2 Johnson et al., 2022

**SARS-CoV-2**

COVID-19 Krasemann et al., 2022 HistoSure SARS-CoV-2 Nsp3 RNA HistoSure SARS-CoV-2 omicron Krasemann et al., 2022

Sars-CoV-2 SARS-CoV-2 ACE2 2 TMPRSS2 Gupta et al., 2020 ACE2 Ambrocio-Ortiz et al., 2021 ACE2 COVID-19 Gheware et al., 2022

ACE2 K18-hACE2 SARS-CoV-2 McCray Jr. et al., 2006 3 SARS-CoV-2 RNA SARS-CoV-2 Abassi et al., 2023




3x HS-452 111 MAC2 DAPI SARS-CoV-2 Leila Abassi, Marina Greweling-Pils & Luka Čičin-Šain


**COVID-19**

COVID-19 COVID-19 Vanderheiden and Klein, 2022 “” Theoharides and Kempuraj, 2023

ACE2 Vanderheiden and Klein, 2022 TMPRSS2 neuropilin-1 NRP1 SARS-CoV-2 Davies et al., 2020

Sars-CoV K18-hACE2 4x5x






4 SARS-Cov-2 #4A8 cat. no. [HS-452 011](#), 1:1000; PFA SARS-CoV-2 K18-hACE2 A DAPI


Čičin-Šain

5 Sars-Cov-2 #53E2 cat. no. [HS-452 111](#), 1:1000; DAB SARS-CoV-2 A K18-hACE2

Čičin-Šain

SARS-CoV-2 #6 #7





**6** **CD11b** cat. no. [HS-384 117](#), 1:200, DAB, PBS, K18-hACE2

Čičin-Šain, Kröger

**7** **Chil3** cat. no. [HS-442 017](#), 1:200, DAB, PBS, K18-hACE2

Čičin-Šain, Kröger

COVID-19 Matschke et al., 2022; Theoharides and Kempuraj, 2023; Radke et al., 2024

“” Theoharides and Kempuraj, 2023

☒ ☒

Cat. No.	Product Description	Application	Quantity	Price	Cart
<a href="#">HS-452 111</a>	Nucleocapsid CoV-1/2, mouse, IgG	WB ICC IHC IHC-P (FFPE)	200 µl	US\$420.00	
<a href="#">HS-452 111BT</a>	Nucleocapsid CoV-1/2, mouse, IgG, biotin	IHC-P (FFPE) ELISA	100 µg	US\$470.00	
<a href="#">HS-452 011</a>	Nucleocapsid CoV-2, mouse, IgG	WB ICC IHC IHC-P (FFPE) ELISA	200 µl	US\$420.00	
<a href="#">HS-452 011BT</a>	Nucleocapsid CoV-2, mouse, IgG, biotin	IHC-P (FFPE)	100 µg	US\$470.00	

Result count: 4

Christel Bonnas  
HistoSure  
Christel HistoSure  
HistoSure



☒ ☒ ☒ ☒

Abassi et al., 2023. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. [PMID: 38005829](#)

Ambrocio-Ortiz et al., 2021. Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. [PMID: 34451902](#)

Davies et al., 2020. Neuropilin 1 as a new potential SARS CoV 2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID 19. [PMID: 33000221](#)

Gheware et al., 2022. ACE2 protein expression in lung tissues of severe COVID-19 infection. [PMID: 35260724](#)

Gupta et al. 2020. Extrapulmonary manifestations of COVID-19. [PMID: 32651579](#)

Johnson et al., 2022. Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. [PMID: 34671771](#)

Krasemann et al., 2022. Assessing and improving the validity of COVID-19 autopsy studies - a multicenter approach to establish essential standards for immunohistochemical and ultrastructural analyses. [PMID: 35930888](#)

Magazine et al., 2022. Mutations and Evolution of the SARS-CoV-2 Spike Protein. [PMID: 35337047](#)

Matschke et al., 2022. Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls. [PMID: 35785352](#)

McCray PB Jr. et al., 2006. Lethal infection in K18-hACE2 mice infected with SARS-CoV. [PMID: 17079315](#)

Pizzato et al., 2022. SARS-CoV-2 and the Host Cell: A Tale of Interactions. <https://doi.org/10.3389/fviro.2021.815388>

Synowiec et al., 2021. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. [PMID: 33441314](#)

Theoharides and Kempuraj, 2023. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. [PMID: 36899824](#)

Radke et al., 2024. Proteomic and transcriptomic profiling of brainstem, cerebellum and olfactory tissues in early- and late-phase COVID-19. [PMID: 38366144](#)

Vanderheiden and Klein 2022. Neuroinflammation and COVID-19. [PMID: 35863101](#)